<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290004</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-0223</org_study_id>
    <nct_id>NCT00290004</nct_id>
  </id_info>
  <brief_title>Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</brief_title>
  <official_title>Phase I/II Trial of Weekly Motexafin Gadolinium (MGd) for Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety, toxicities, dosage and response&#xD;
      rate for an investigational drug, motexafin gadolinium, administered to patients with chronic&#xD;
      lymphocytic leukemia or small lymphocytic lymphoma. The secondary purpose of this study is to&#xD;
      evaluate the clinical benefit rate, the time it takes for a patient's chronic lymphocytic&#xD;
      leukemia or small lymphocytic lymphoma to worsen, the duration of response and the time&#xD;
      during which patients survive without chronic lymphocytic leukemia or small lymphocytic&#xD;
      lymphoma worsening. Additionally, the patient's response to motexafin gadolinium will be&#xD;
      compared to the response of the patient's cells in a laboratory to motexafin gadolinium.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) of MGd when administered once weekly to patients with relapsed or refractory CLL/SLL</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the dose-limiting toxicities (DLTs) of MGd when administered once weekly to patients with relapsed or refractory CLL/SLL</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the complete and partial response rate in patients with relapsed or refractory CLL/SLL when administered MGd once weekly at the MTD</measure>
  </primary_outcome>
  <enrollment>35</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>motexafin gadolinium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  CLL as defined by the NCI 96 criteria (exception; patients may have bright surface&#xD;
             immunoglobulin staining if negative for t[11;14] translocation or cyclin D1) or SLL as&#xD;
             defined by WHO classification criteria and is refractory or relapsed as defined by one&#xD;
             of the following:&#xD;
&#xD;
               -  Refractory disease: progressive disease while on therapy&#xD;
&#xD;
               -  Relapsed disease: progressive disease after at least one treatment course of&#xD;
                  therapy with disease response or stabilization&#xD;
&#xD;
          -  ECOG performance status score of 0, 1, or 2&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laboratory values of:&#xD;
&#xD;
               -  Platelet count &lt; 30,000/µL&#xD;
&#xD;
               -  AST or ALT &gt; 2 x ULN (upper limit of normal)&#xD;
&#xD;
               -  Total bilirubin &gt; 2 x ULN&#xD;
&#xD;
               -  Creatinine &gt; 2 mg/dL&#xD;
&#xD;
          -  Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids (&gt; 10 mg oral&#xD;
             prednisone or equivalent), or systemic biologic anticancer therapy within 21 days&#xD;
             before beginning study treatment&#xD;
&#xD;
          -  Major surgery or hospitalization for a serious illness within the last 3 months&#xD;
&#xD;
          -  Greater than three prior regimens (where a regimen is defined as a treatment for&#xD;
             CLL/SLL given initially or after disease progression)&#xD;
&#xD;
          -  Prior malignancy requiring current or prior treatment within the past 5 years, except&#xD;
             for cervical neoplasia in situ and non-melanomatous skin cancer&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Evens, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert H Lurie Comprehensive Cancer Center of Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil E Kay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Norris Cancer Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>February 8, 2006</study_first_submitted>
  <study_first_submitted_qc>February 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2006</study_first_posted>
  <last_update_submitted>September 10, 2008</last_update_submitted>
  <last_update_submitted_qc>September 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2008</last_update_posted>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Small Lymphocytic Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Motexafin Gadolinium</keyword>
  <keyword>Relapsed Chronic Lymphocytic Leukemia</keyword>
  <keyword>Relapsed Small Lymphocytic Lymphoma</keyword>
  <keyword>Refractory Chronic Lymphocytic Leukemia</keyword>
  <keyword>Refractory Small Lymphocytic Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

